Precision Biosciences (DTIL) Assets Average (2019 - 2026)
Precision Biosciences (DTIL) posted quarterly Assets Average of $149.2 million for Q1 2026, up 14.38% year-over-year from $130.4 million in Q1 2025, and up 20.32% quarter-over-quarter from $124.0 million in Q4 2025.
Precision Biosciences (DTIL) Assets Average (2019 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Assets Average for 8 consecutive years, with $149.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 14.38% year-over-year to $149.2 million; the TTM figure through Mar 2026 stood at $149.2 million (up 14.38% YoY), while the FY2025 annual figure was $145.4 million, down 1.81% from the prior year.
- Assets Average climbed to $149.2 million in Q1 2026 per DTIL's latest filing, from $124.0 million in the prior quarter.
- Across five years, Assets Average topped out at $284.4 million in Q3 2022 and bottomed at $101.2 million in Q3 2025.
- Historically, Assets Average has averaged $176.3 million across 5 years, with a median of $172.3 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average gained 24.4% — and 2023, when it plunged 39.17%.
- Precision Biosciences' Assets Average stood at $255.0 million in 2022, then slumped by 36.43% to $162.1 million in 2023, then decreased by 10.64% to $144.8 million in 2024, then dropped by 14.4% to $124.0 million in 2025, then gained by 20.32% to $149.2 million in 2026.
- Business Quant data shows DTIL's Assets Average at $149.2 million in Q1 2026, $124.0 million in Q4 2025, and $101.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 19.82 Bn |
| 10 | Precision Biosciences | 232.58 Mn | 145.03 Mn | - | 134.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 134.91 Mn |
| Mar 31, 2026 | 149.15 Mn |
| Dec 31, 2025 | 123.96 Mn |
| Sep 30, 2025 | 101.22 Mn |
| Jun 30, 2025 | 116.67 Mn |
| Mar 31, 2025 | 130.40 Mn |
| Dec 31, 2024 | 144.82 Mn |
| Sep 30, 2024 | 159.53 Mn |
| Jun 30, 2024 | 175.27 Mn |
| Mar 31, 2024 | 172.26 Mn |
| Dec 31, 2023 | 162.06 Mn |
| Sep 30, 2023 | 173.02 Mn |
| Jun 30, 2023 | 193.10 Mn |
| Mar 31, 2023 | 221.34 Mn |
| Dec 31, 2022 | 254.95 Mn |
| Sep 30, 2022 | 284.45 Mn |
| Jun 30, 2022 | 239.26 Mn |
| Mar 31, 2022 | 196.42 Mn |
| Dec 31, 2021 | 219.35 Mn |
| Sep 30, 2021 | 228.66 Mn |